Genmab (GMAB) Announced New Sales Figures for DARZALEX

Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right NowOn July 16, Genmab A/S (NASDAQ:GMAB) announced new sales figures for DARZALEX as of the second quarter of 2025.

The company reported that the total worldwide sales reached $3.539 billion. Out of this, the US sales accounted for $2.017 billion, whereas sales from the rest of the world reached $1.521 billion. Management noted that the DARZALEX includes both intravenous and subcutaneous forms. Moreover, Genmab A/S (NASDAQ:GMAB) does not sell DARZALEX directly; instead, Johnson & Johnson (NYSE:JNJ) holds the exclusive license to develop and commercialize the drug, and the company receives royalties based on the sales.

Genmab (GMAB) Announced New Sales Figures for DARZALEX

A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company from Denmark that develops antibody-based medicines to treat cancer and other diseases.

While we acknowledge the potential of GMAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GMAB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.